Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Large & Mid Cap Fund median (35 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 26 Feb 2015 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty Midcap 150 history starts 14 Jan 2019, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | LIC MF Large & Mid Cap Fund |
|---|---|
| 26 Feb 2015 | ₹100.00 |
| 10 Feb 2016 | ₹87.54 |
| 25 Jan 2017 | ₹116.45 |
| 09 Jan 2018 | ₹149.94 |
| 25 Dec 2018 | ₹125.45 |
| 09 Dec 2019 | ₹139.40 |
| 23 Nov 2020 | ₹151.13 |
| 07 Nov 2021 | ₹215.81 |
| 22 Oct 2022 | ₹204.48 |
| 07 Oct 2023 | ₹221.07 |
| 20 Sep 2024 | ₹325.99 |
| 05 Sep 2025 | ₹307.53 |
| 20 Aug 2026 | ₹321.39 |
| Metric | LIC · Regular · IDCW NAV ₹32.19 Very High risk ★★★★☆ | Category median Large & Mid Cap Fund · 35 funds |
|---|---|---|
| +3.04% | +3.02% | |
| +14.93% | +9.47% | |
| +10.24% | +9.57% | |
| +11.31% | +8.51% | |
| +10.71% | +8.27% | |
| +10.97% | — | |
| +12.00% | +10.05% | |
| +12.16% | +9.17% | |
| +12.18% | +6.32% | |
| Risk | ||
| 15.55% | 15.59% | |
| 0.54 | 0.10 | |
| 0.74 | 0.12 | |
| -34.35% | -42.76% | |
| Nifty Midcap 150 | — | |
| -1.48% | -5.64% | |
| 0.89 | 0.85 | |
| 88.7% | 79.3% | |
| 93.0% | 97.2% | |
| 2.90% | 2.30% | |
| ₹3,133Cr | ₹4,527Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹200 | — | |
| ₹5.00K | — | |
| 39% | 40% | |
| Yogesh Patil | — | |
| 26 Feb 2015 | — | |
| 42 | — | |
| 33.3% | — | |
| 1.5% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.